Clovis Oncology Inc (CLVS), ACADIA Pharmaceuticals Inc. (ACAD): Healthcare Companies to Watch Out For

Similarly ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is also one of the 200%-plus gainers. The stock is due to the respond to data for its psychosis drug, pimavanserin, which is used for the treatment of Parkinson’s disease. The company proved through clinical trials that pimavanserin helped in the reduction of psychotic events. Moreover, in March this year, the company disclosed that Phase 3 trials would not be required for the drug, which indicates that the company is now waiting to get FDA approval. Thus, I believe that its stock still has a margin to go up once it is ready for the FDA approval.

Final assessment

I would like to see how Clovis Oncology Inc (NASDAQ:CLVS) is going to perform until the end of next year. The company has the potential to grow more, and once its leading components, i.e. CO-1686 and rucaprib, come near to getting FDA approvals, the company should once more soar in to the skies.

usman iftikhar has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. usman is a member of The Motley Fool Blog Network — entries represent the personal opinion of the blogger and are not formally edited.

The article Three Healthcare Companies to Watch Out For originally appeared on Fool.com and is written by usman iftikhar.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.